John Anthonypillai
Allergy · Bel Air, MDNPI 1093128456
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 265 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,585 and has fallen 76.0% since, to $621 in 2025.
Across 265 payments — averaging $28.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Sanofi$915
- Regeneron Healthcare Solutions, Inc.$690
- Amgen$467
- CSL Behring$395
- plus $2K from 19 others
What the payments were for
- Food & beverage$7,51598%
- Education$1302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $1,539 |
| GSK | 46 | $1,171 |
| Sanofi | 29 | $915 |
| Regeneron Healthcare Solutions, Inc. | 29 | $690 |
| Amgen | 11 | $467 |
| CSL Behring | 10 | $395 |
| Genentech USA, Inc. | 10 | $269 |
| Optinose US, Inc. | 12 | $258 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $258 |
| Kaleo, Inc. | 10 | $224 |
| Novartis | 10 | $203 |
| Incyte Corporation | 6 | $200 |
| Grifols USA, LLC | 7 | $149 |
| AbbVie | 4 | $144 |
| Pfizer | 5 | $115 |
| Aimmune Therapeutics, Inc. | 5 | $108 |
| Biocryst US Sales Co., LLC | 4 | $94 |
| Octapharma USA, Inc. | 4 | $86 |
| Sanofi-aventis U.S. LLC | 1 | $77 |
| Teva Pharmaceuticals USA, Inc. | 4 | $69 |
| Blueprint Medicines Corporation | 3 | $68 |
| Ionis Pharmaceuticals, Inc. | 1 | $50 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $47 |
| Eyevance Pharmaceuticals LLC | 1 | $25 |
| Abbott | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$366
- AIRSUPRA$345
- BREZTRI$253
- TRELEGY ELLIPTA$125
- OPZELURA$116
How this compares
$7,645 in reported general payments places this provider in the 55th percentile of 29 allergy providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 12 | $45,274 |
| XolairOmalizumab | 13 | $35,395 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $27,219 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $15,070 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,471 |
| Arnuity ElliptaFluticasone Furoate | 26 | $6,429 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $6,120 |
| Epinephrine | 18 | $4,699 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,313 |
| Azelastine Hcl | 61 | $1,704 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $1,641 |
| Fluticasone Propionate | 67 | $1,361 |
| Levocetirizine Dihydrochloride | 57 | $1,148 |
| Montelukast Sodium | 70 | $1,102 |
| Desloratadine | 23 | $967 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,171 | $48,71881 claims |
| AstraZenecaSymbicort | $1,539 | $6,12013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 29 allergy providers in Maryland.
Other allergy in Bel Air
- Huamin LiWheaton$576K
- David GoldenBaltimore$197K
- Jody TverskyBaltimore$175K
- Sarbjit SainiBaltimore$174K
- Jonathan MatzWhite Marsh$147K
- Newton AdkinsonBaltimore$61K
- Brett CoonsJb Andrews$49K
- Peter CreticosBaltimore$22K
- David SchwartzBethesda$15K
- Asek MakiaMitchellville$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.